Abstract
| Original language | English |
|---|---|
| Journal | Vaccine |
| Volume | 36 |
| Issue number | 2 |
| Pages (from-to) | 227-236 |
| ISSN | 0264-410X |
| DOIs | |
| Publication status | Published - 2018 |
Bibliographical note
This is an open access article under the CC BY-NC-ND license.Keywords
- Porcine reproductive and respiratory syndrome virus
- Vaccination
- Swine
- PRRSV
Cite this
}
Efficacy and safety of simultaneous vaccination with two modified live virus vaccines against porcine reproductive and respiratory syndrome virus types 1 and 2 in pigs. / Kristensen, Charlotte S.; Kvisgaard, Lise Kirstine; Pawlowski, Maciej; Holmgaard Carlsen, S.; Hjulsager, Charlotte Kristiane; Heegaard, Peter Mikael Helweg; Bøtner, Anette; Stadejek, T.; Haugegaard, Svend; Larsen, L.E.
In: Vaccine, Vol. 36, No. 2, 2018, p. 227-236.Research output: Contribution to journal › Journal article › Research › peer-review
TY - JOUR
T1 - Efficacy and safety of simultaneous vaccination with two modified live virus vaccines against porcine reproductive and respiratory syndrome virus types 1 and 2 in pigs
AU - Kristensen, Charlotte S.
AU - Kvisgaard, Lise Kirstine
AU - Pawlowski, Maciej
AU - Holmgaard Carlsen, S.
AU - Hjulsager, Charlotte Kristiane
AU - Heegaard, Peter Mikael Helweg
AU - Bøtner, Anette
AU - Stadejek, T.
AU - Haugegaard, Svend
AU - Larsen, L.E.
N1 - This is an open access article under the CC BY-NC-ND license.
PY - 2018
Y1 - 2018
N2 - The objective of the study was to compare responses of pigs vaccinated with a PRRS MLV vaccine against PRRSV-1 or PRRSV-2 with the responses of pigs vaccinated simultaneously with both vaccines. Furthermore, the efficacy of the two PRRSV MLV vaccination strategies was assessed following challenge. The experimental design included four groups of 4-weeks old SPF-pigs. On day 0 (DPV0), groups 1–3 (N = 18 per group) were vaccinated with modified live virus vaccines (MLV) containing PRRSV-1 virus (VAC-T1), PRRSV-2 virus (VAC-T2) or both (VAC-T1T2). One group was left unvaccinated (N = 12). On DPV 62, the pigs from groups 1–4 were mingled in new groups and challenged (DPC 0) with PRRSV-1, subtype 1, PRRSV-1, subtype 2 or PRRSV-2. On DPC 13/14 all pigs were necropsied. Samples were collected after vaccination and challenge. PRRSV was detected in all vaccinated pigs and the majority of the pigs were positive until DPV 28, but few of the pigs were still viremic 62 days after vaccination. Virus was detected in nasal swabs until DPV 7–14. No overt clinical signs were observed after challenge. PRRSV-2 vaccination resulted in a clear reduction in viral load in serum after PRRSV-2 challenge, whereas there was limited effect on the viral load in serum following challenge with the PRRSV-1 strains. Vaccination against PRRSV-1 had less impact on viremia following challenge. The protective effects of simultaneous vaccination with PRRSV Type 1 and 2 MLV vaccines and single PRRS MLV vaccination were comparable. None of the vaccines decreased the viral load in the lungs at necropsy. In conclusion, simultaneous vaccination with MLV vaccines containing PRRSV-1 and PRRSV-2 elicited responses comparable to single vaccination and the commercial PRRSV vaccines protected only partially against challenge with heterologous strains. Thus, simultaneous administration of the two vaccines is an option in herds with both PRRSV types.
AB - The objective of the study was to compare responses of pigs vaccinated with a PRRS MLV vaccine against PRRSV-1 or PRRSV-2 with the responses of pigs vaccinated simultaneously with both vaccines. Furthermore, the efficacy of the two PRRSV MLV vaccination strategies was assessed following challenge. The experimental design included four groups of 4-weeks old SPF-pigs. On day 0 (DPV0), groups 1–3 (N = 18 per group) were vaccinated with modified live virus vaccines (MLV) containing PRRSV-1 virus (VAC-T1), PRRSV-2 virus (VAC-T2) or both (VAC-T1T2). One group was left unvaccinated (N = 12). On DPV 62, the pigs from groups 1–4 were mingled in new groups and challenged (DPC 0) with PRRSV-1, subtype 1, PRRSV-1, subtype 2 or PRRSV-2. On DPC 13/14 all pigs were necropsied. Samples were collected after vaccination and challenge. PRRSV was detected in all vaccinated pigs and the majority of the pigs were positive until DPV 28, but few of the pigs were still viremic 62 days after vaccination. Virus was detected in nasal swabs until DPV 7–14. No overt clinical signs were observed after challenge. PRRSV-2 vaccination resulted in a clear reduction in viral load in serum after PRRSV-2 challenge, whereas there was limited effect on the viral load in serum following challenge with the PRRSV-1 strains. Vaccination against PRRSV-1 had less impact on viremia following challenge. The protective effects of simultaneous vaccination with PRRSV Type 1 and 2 MLV vaccines and single PRRS MLV vaccination were comparable. None of the vaccines decreased the viral load in the lungs at necropsy. In conclusion, simultaneous vaccination with MLV vaccines containing PRRSV-1 and PRRSV-2 elicited responses comparable to single vaccination and the commercial PRRSV vaccines protected only partially against challenge with heterologous strains. Thus, simultaneous administration of the two vaccines is an option in herds with both PRRSV types.
KW - Porcine reproductive and respiratory syndrome virus
KW - Vaccination
KW - Swine
KW - PRRSV
U2 - 10.1016/j.vaccine.2017.11.059
DO - 10.1016/j.vaccine.2017.11.059
M3 - Journal article
VL - 36
SP - 227
EP - 236
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 2
ER -